Tislelizumab（neoadjuvant）

DRUG2 trials

Sponsors

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Conditions

Head and Neck Squamous Cell CarcinomaHead and Neck Squamous Cell Carcinomas

Phase 2

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma

RecruitingNCT06323369

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityHead and Neck Squamous Cell Carcinoma

Start: 2024-03-25End: 2029-09-25Target: 154Updated: 2024-05-17

Phase 3

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)

RecruitingNCT05582265

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityHead and Neck Squamous Cell Carcinomas

Start: 2022-10-28End: 2030-10-31Target: 537Updated: 2024-05-17